Sorafenib Tosylate CAS 475207-59-1 Tsarkakewa ≥99.0% (HPLC) API Babban Inganci
Samar da Kasuwancin Sorafenib Tosylate da Matsakaici masu alaƙa:
Sorafenib Tosylate CAS: 475207-59-1
Sorafenib CAS: 284461-73-0
4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS: 220000-87-3
4- (4-Aminophenoxy) -N-Methylpicolinamide CAS: 284462-37-9
4-Chloro-3- (Trifluoromethyl) phenyl Isocyanate CAS: 327-78-6
| Sunan Sinadari | Sorafenib Tosylate |
| Makamantu | Nexavar;4-[4-[3-[4-Chloro-3- (Trifluoromethyl) phenyl] ureido] phenoxy] -N-Methylpicolinamide 4-Methylbenzenesulfonate;4-[4-[4-Chloro-3- (Trifluoromethyl) phenyl] carbamamido] phenoxy] -N-Methyl-2-Pyridinecarboxamide 4-Methylbenzenesulfonate;BAY 43-9006 Tosylate |
| Lambar CAS | 475207-59-1 |
| Matsayin Hannun jari | A Hannun jari, Ma'aunin Samfuran Har zuwa Daruruwan Kilogram |
| Tsarin kwayoyin halitta | C21H16ClF3N4O3.C7H8O3S |
| Nauyin Kwayoyin Halitta | 637.03 |
| Matsayin narkewa | 225.0 zuwa 230.0 ℃ |
| M | Hankalin iska, Mai jin zafi |
| Solubility | Mai narkewa a cikin Ruwa (<1 mg / ml) a 25 ℃, DMSO (127 mg / ml) a 25 ℃, da Ethanol (<1 mg / ml) a 25 ℃ |
| Yanayin jigilar kaya | Cool & bushe wuri (2 ~ 8 ℃), Kare daga Haske |
| COA & MSDS | Akwai |
| Rayuwar Rayuwa | Shekaru 2 Idan An Ajiyesu Da Kyau |
| Alamar | Ruifu Chemical |
| Abu | Ƙayyadaddun bayanai | Sakamako |
| Bayyanar | Rawaya Mai Haske ko Farin Foda | Ya bi |
| Tsarkake / Hanyar Bincike | ≥99.0% (HPLC) | 99.8% |
| Matsayin narkewa | 225.0 ~ 230.0 ℃ | Ya bi |
| Karfe masu nauyi | ≤10ppm | <10ppm |
| Asara akan bushewa | ≤0.50% | 0.12% |
| Ragowa akan Ignition | ≤0.20% | 0.10% |
| Duk Wani Rashin Tsabtace Guda Daya | ≤0.50% | Ya bi |
| Jimlar ƙazanta | ≤0.50% | Ya bi |
| Farashin NMR Spectrum | Yayi daidai da Tsarin | Ya bi |
| Matsayin Gwaji | Matsayin Kasuwanci | Ya bi |
| Amfani | Sorafenib Tosylate (CAS: 475207-59-1) a cikin maganin RCC & HCC | |
Kunshin:Bottle, Aluminum tsare jakar, 25kg / Kwali Drum, ko bisa ga abokin ciniki ta bukata.
Yanayin Ajiya:Ajiye a cikin akwati da aka rufe sosai.Ajiye a cikin sanyi, bushe (2 ~ 8 ℃) da ma'ajin da ke da isasshen iska daga abubuwan da ba su dace ba.Kare daga haske da danshi.
Jirgin ruwa:Isar da shi zuwa duniya ta iska, ta FedEx / DHL Express.Bayar da isarwa cikin sauri kuma abin dogaro.
Lambobin haɗari 36/37/38 - Haɗa kai ga idanu, tsarin numfashi da fata.
Bayanin Tsaro S28 - Bayan hulɗa da fata, wanke nan da nan da sabulu-suds mai yawa.
S26 - Idan ana hulɗa da idanu, kurkura nan da nan da ruwa mai yawa kuma ku nemi shawarar likita.
Sorafenib Tosylate (CAS: 475207-59-1) wani sabon nau'i ne na magungunan rigakafin tumor da aka yi niyya da yawa, Kamfanin Magunguna na Bayer na Jamus ne ya ƙirƙira shi, kuma ya nuna faɗuwar aikin antitumor a cikin gwaje-gwajen dabbobi na asali.Ana samun Sorafenib a cikin allunan 200-MG don gudanar da baki kuma ana amfani dashi a cikin jiyya na RCC da HCC.Sorafenib Tosylate na iya yin tasiri a lokaci guda tare da ƙwayoyin tumor da kuma tasoshin jini.Yana da tasirin antitumor sau biyu: yana iya toshe hanyoyin siginar siginar tantanin halitta wanda RAF/MEK/ERK ke shiga tsakani don hana haɓakar ƙwayar ƙwayar cuta kai tsaye, yayin da kuma yana hana VEGF da abubuwan haɓakar haɓakar platelet (PDGF) don hana samuwar sabon ƙwayar ƙwayar cuta. tasoshin, don haka a kaikaice yana hana haɓakar ƙwayar ƙwayar cuta.
Sorafenib Tosylate, sunan kasuwanci Nexavar, kamfanin Bayer Pharmaceuticals ne ya fara haɓaka shi a Jamus.Sorafenib Tosylate shine mai hanawa mai yawa-kinase wanda za'a iya amfani dashi don magance cututtuka irin su ciwon daji.A cikin Disamba 2005, FDA ta Amurka ta amince da shi azaman magani na farko don maganin ciwon daji na koda.A watan Agusta 2009, an jera shi a hukumance a kasar Sin tare da amincewar Hukumar Kula da Abinci da Magunguna ta Jiha.
Sorafenib Tosylate sune tyrosine kinases (VEGFR da PDGFR) da RAF / MEK / ERK cascade inhibitors, suna aiki lokaci guda akan Raf-1, wtBRAF da V599EBRAF, tare da IC50 na 6 nM, 22 nM da 38 nM, bi da bi.
Sorafenib Tosylate na iya hana nau'in kinase iri-iri da ke wanzuwa a kan tantanin halitta da kuma tantanin halitta, ciki har da RAF kinase, mai karɓa na endothelial girma factor receptor-2 (VEGFR-2), vascular endothelial growth factor receptor-3 (VEGFR-3), platelet. -wanda aka samu girma mai karɓa-β (PDGFR-β), KIT da FLT-3.Ana iya ganin cewa sorafenib toluenesulfonate yana da tasirin anti-tumor dual.A gefe guda, zai iya hana ci gaban ƙwayar cuta kai tsaye ta hanyar hana hanyar siginar RAF / MEK / ERK;a gefe guda, yana iya hana VEGFR da PDGFR.Kuma toshe samuwar ƙari neovascularization, a kaikaice hana ci gaban ƙari Kwayoyin.Sorafenib Tosylate shine mafi kyawun magani don maganin ciwon hanta mai ci gaba ta hanyar gudanar da tsarin, kuma zai iya zama sabon ma'aunin magani don maganin wannan cuta.
Sorafenib Tosylate sau ɗaya-yau da kullun na yau da kullun na kayan maye, wanda ba shi da ƙarancin cutar sel, ƙwaƙwalwar ƙwaƙwalwar ƙwayar cuta, ƙwaƙwalwar ƙwaƙwalwar ƙwaƙwalwar ƙwaƙwalwa da kuma ciwon daji na fata da kuma ciwon jini pollanel celaroma carfinoma model, RENCA model.
